Analysis of the efficacy and related factors of ventriculoperitoneal shunt for AIDS with cryptococcal meningitis

Zhaohui Chai¹, Yikai Shou², Rajneesh Mungur³, Jiangbiao Gong³, Peidong Zheng³ and Jiesheng Zheng³*¹

¹Department of Neurosurgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China, ²School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, China, ³Department of Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Background: Cryptococcus neoformans is an opportunistic pathogen, which is more common in patients with AIDS. Increased intracranial pressure (ICP) is an important complication of cryptococcal meningitis (CM) and affects the therapeutic effect of CM.

Objective: To evaluate the effect and treatment for the management of ventriculoperitoneal shunt (VPS) in the treatment of AIDS complicated with CM and to analyze the factors associated with VPS and the indices affecting the outcome of CM patients.

Methods: A retrospective case study was conducted on patients with CM treated in the First Affiliated Hospital of Zhejiang University School of Medicine from 2011 to 2019. The Chi-square test was used for categorical variables and the Student’s t-test was used for continuous variables. Multivariable analysis of baseline factors related to VPS placement was performed with stepwise logistic regression analysis, factors associated with the outcome of these patients were studied by Cox regression analysis, and Kaplan–Meier survival curves were constructed to assess the outcome of patients.

Results: There were 96 patients with AIDS complicated with CM. VPS had a great effect on the patients, especially those with ICP > 350 mmH2O. The outcome, including the mortality rate and modified Rankin scale (MRS) score of these patients, significantly improved after the placement of VPS. The Karnofsky performance status (KPS) scores of patients whose ICP > 350 mmH2O improved from 39.3 ± 21.3 at baseline to 88.7 ± 26.9 at 3 months after VPS, better than those without VPS. Multivariable analysis showed that visual impairment (OR, 0.026; 95% CI, 0.001, 0.567; P = 0.021) and ICP > 350 mmH2O (OR, 0.026; 95% CI, 0.002, 0.293; P = 0.003) were related elements with the placement of shunt, and KPS score (HR, 0.968; 95% CI, 0.943, 0.993; P = 0.013) and ICP > 350 mmH2O (HR, 2.801; 95% CI, 1.035, 7.580; P = 0.043) were indices of the outcome of AIDS patients with CM. For patients with ICP > 350 mmHg, Kaplan–Meier analysis showed that the 3-year outcome of patients with VPS was better than that of patients without VPS (P = 0.0067).

Conclusion: VPS was associated with better 3-year survival rates, and postshunt placement complications like infections were rare. The identification of factors related to VPS in the initial diagnosis of CM can contribute to more active management and improve the outcome.
Introduction

*Cryptococcus neoformans* is a common conditional pathogen and a common cause of fungal meningitis. The infection rates of *C. neoformans* in AIDS patients are 23% and 48% (1). In many cases, the outcome of this opportunistic infection is not satisfactory. Even if some patients take antifungal therapies, the mortality rate is still high, ranging from 30% to 50% (2). Even with effective antiretroviral therapy (HAART), cryptococcal meningitis (CM) kills 15% of patients every year (3). Therefore, timely and effective treatment should be given to patients with CM in order to improve the outcome of patients with AIDS.

The main symptoms of CM are headache, fever, nausea, vomiting, visual and hearing impairment, and changes in mental state (3). In addition, increased intracranial pressure (ICP) is an important complication, which may lead to disability or even death due to cerebral hernia if not treated in time (2). In patients with ICP, frequent lumbar puncture is required to reduce the pressure and release symptoms. Dehydration drugs such as mannitol and acetazolamide have no obvious effect on reducing intracranial pressure, and the adverse effect of the disturbance of electrolytes limits the application, especially for acetazolamide (4). Uncontrolled increased ICP is defined as an extremely high opening intracranial pressure (>350 mmH2O) and failure to control increased ICP symptoms through frequent lumbar punctures and other medical procedures such as glucocorticoids, mannitol, or acetazolamide (5). For a small number of patients, lumbar drainage (6), ventricular drainage (7), Ommaya tube implantation (8), and ventriculoperitoneal shunt (VPS) (9–12) are required to reduce intracranial pressure. But in resource-limiting areas, where most AIDS-related CM cases are reported, the availability of these procedures is lacking. It is difficult to identify patients who require invasive procedures. Studies have shown that VPS can significantly improve the outcome of such patients (13). Therefore, we studied the factors related to VPS in AIDS patients complicated with CM, the effect of VPS on the outcome of patients with AIDS complicated with CM, and the factors related to the outcome, in order to have a more comprehensive understanding of patients who are suitable for VPS.

Materials and methods

Subjects

We conducted a retrospective observational cohort study of patients with AIDS complicated with CM. The included cases were diagnosed in the First Affiliated Hospital of Zhejiang University School of Medicine from January 2011 to September 2019. CM is defined as *C. neoformans* discovered in at least one cerebrospinal fluid (CSF) culture, *C. neoformans* capsule antigen positive, cryptococcal ink negative staining positive, and typical CSF characteristics and clinical manifestations. The manifestation of the CSF in patients with CM is consistent with that in patients with lyphocytic meningitis. Generally, the number of white blood cells is less than 150 × 10³/μL; the protein levels increase and those of glucose decrease. The protocol was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University School of Medicine. In order to avoid interfering with the statistical results, the exclusion criteria were as follows: (1) Accompanied by other central nervous system infections; (2) Recurrent cryptococcal meningitis; (3) Sequelae of nervous system injury caused by previous head injury, cerebral infarction, or intracranial hemorrhage; (4) VPS was performed in other hospitals; (5) Implanted Ommaya tube or performed ventricular drainage after diagnosis in our hospital.

Methods

According to the above criteria, 96 cases were included, which were divided into VPS group and non-VPS group according to the performance or non-performance of the shunt procedure. A total of 30 patients (31.3%) underwent VPS after diagnosis, of which 27 were males and 3 were females, with an average age of 34.7 ± 9.5 years. A total of 66 patients (68.7%) did not undergo VPS, of which 65 were males and 1 was a female, with an average age of 38.8 ± 11.8 years. VPS was undertaken in all patients using a Medtronic® system. We analyzed the data of patients with CM at the time of initial diagnosis in order to reduce the bias caused by physicians’ different preferences for lumbar puncture and shunt. The clinical features of the two groups and the characteristics of patients with ICP > 350 mmH2O were compared. The factors associated with VPS, the difference of outcome between the two groups, and the indices related to the outcome were analyzed. Improvement is defined as a reduction of clinical symptoms and signs, and a good outcome is defined as a patient who is still alive, with no symptoms, or with only a few symptoms, and is able to take care of himself/herself. This corresponds to a patient with a modified Rankin scale (MRS) score <2. A poor outcome is defined as the death of a patient or the retention of severe symptoms and thus unable to take care of himself/herself, and
this corresponds to a patient with a MRS score ≥2. Hydrocephalus was diagnosed as a dilation of the temporal horn of the lateral ventricle, without significant brain atrophy, and/or an Evans’s ratio of >0.30 on the initial and/or subsequent CT or MRI. Evans’s ratio is the ratio of the width of the bilateral frontal horn of the ventricle to the maximum biparietal diameter.

Statistical analysis

The clinical results and biochemical indices were expressed as mean ± standard deviation. The continuous variables such as age, days of diagnosis of AIDS on admission, time from onset to operation (days), karnofsky performance status (KPS) score, CSF nucleated cells, CSF glucose, CSF chloride, CSF protein, and CSF WBC counts, (10⁶/L), mean (SD) were compared between the VPS group and the non-VPS group. CD4+ T-cell count were tested by using independent samples. Statistical analysis was conducted using SPSS software, version 23.0.

Baseline data of patients

The clinical manifestations of the patients mainly include headache, fever, cranial nerve paralysis, and mental state changes. There was no significant difference in these aspects between the two groups (P > 0.05). The KPS score of the VPS group was lower than that of the non-VPS group. The ICP of patients in the VPS group was 404.2 ± 39.8, while the ICP of patients in the non-VPS group was 301.7 ± 105.0, and there was a significant difference between the two groups (P < 0.001). The C. neoformans count in patients with VPS was higher than that in patients without VPS. The incidence of neck stiffness in the VPS group (70.0%) was higher than that in the non-VPS group (47.0%) (P < 0.05). The incidence of convulsions in the VPS group (20.0%) was higher than that in the non-VPS group (1.5%) (P < 0.05). There were 11 cases of visual impairment and 2 cases of hearing impairment, and there was significant difference between the two groups (P < 0.05). The average length of stay in the non-VP shunt group was shorter than that in the VP shunt group, but there was no significant difference between the two groups (Table 1). The ICP significantly decreased after VPS (Supplementary Figure S1).

Comparison of patients with ICP > 350 mmH₂O

Nausea, vomiting, and visual impairment in patients with VPS were more obvious than those without VPS. Among the patients who underwent VPS, 5 (17.2%) had convulsions, while those without VPS had no convulsions, and there was a significant difference between the two groups (P < 0.05). At the same time, for patients with ICP > 350 mmHg, the short-term and long-term outcomes (mortality rates, MRS scores) of patients with VPS were better than those of patients without VPS. The KPS score at baseline of patients with VPS was 39.3 ± 21.3, while it was 39.6 ± 18.5 for patients without VPS (P = 0.965), and there were no distinct differences between the

| Characteristics                  | Non-VPS group (n = 30) | VPS group (n = 30) | P-value |
|----------------------------------|------------------------|-------------------|---------|
| Gender (M/F)                     | 65/1                   | 27/3              | 0.054   |
| Age, mean (SD)                   | 38.8(11.8)             | 34.7(9.5)         | 0.100   |
| Days diagnosed AIDS before admission, mean (SD) | 284.1(644.8) | 96.8(392.3) | 0.159   |
| Headache, n (%)                  | 53(80.3)               | 26(68.7)          | 0.393   |
| Fever, n (%)                     | 41(62.1)               | 18(60.0)          | 0.853   |
| Nausea, n (%)                    | 27(40.9)               | 23(76.7)          | 0.001   |
| Emeisis, n (%)                   | 21(31.8)               | 21(70.0)          | <0.001  |
| Visual symptoms, n (%)           | 2(3.0)                 | 9(30.0)           | <0.001  |
| Hearing symptoms, n (%)          | 0(0.0)                 | 2(6.7)            | 0.028   |
| Cranial nerve palsy, n (%)       | 2(3.0)                 | 1(3.3)            | 0.891   |
| Mental status change, n (%)      | 9(13.6)                | 4(13.3)           | 0.968   |
| Neck stiffness, n (%)            | 31(47.0)               | 21(70.0)          | 0.036   |
| Convulsion, n (%)                | 1(1.5)                 | 6(20.0)           | 0.001   |
| KPS, mean (SD)                   | 49.2(22.2)             | 38.7(21.2)        | 0.033   |
| Evans’ ratio                     | 0.25(0.03)             | 0.26(0.03)        | 0.211   |
| ICP, (mmH₂O), mean (SD)          | 301.7(105.0)           | 404.2(39.8)       | <0.001  |
| Ink stain, n (%)                 | 55(83.3)               | 29(96.7)          | 0.088   |
| CSF culture, n (%)               | 46(69.7)               | 26(86.7)          | 0.174   |
| Cryptococcus counts, (10³/L), mean (SD) | 2.6(1.4) | 3.5(1.8) | 0.023   |
| CSF WBC, (10³/L), mean (SD)      | 34.4(95.4)             | 12.0(32.4)        | 0.217   |
| Glucose, mmol/L, mean (SD)       | 2.6(0.9)               | 3.1(1.1)          | 0.019   |
| Protein, g/L, mean (SD)          | 0.7(0.6)               | 0.6(0.4)          | 0.160   |
| Chloride, mmol/L (SD)            | 117.0(6.3)             | 118.0(5.1)        | 0.458   |
| CD4, (10⁶/L) (SD)                | 20.9(37.0)             | 15.5(19.5)        | 0.460   |
| CD4/CD8, mean (SD)               | 0.10(0.09)             | 0.05(0.05)        | 0.007   |
| Hospital stay, mean (SD)         | 38.9(37.8)             | 60.1(67.4)        | 0.055   |

SD, standard deviation; CSF WBC, cerebrospinal fluid white blood cell; VPS, ventriculoperitoneal shunt.
two groups. The KPS score at 3 months of patients with VPS was 88.67 ± 26.92, while it was 58.26 ± 46.96 for patients without VPS (P = 0.012). Table 2 shows a comparison between the two groups. Figure 1 shows the Kaplan–Meier analysis of the 3-year outcome of the two groups.

Table 2. Comparison of basic data between the VPS group and the non-VPS group whose ICP > 350 mmH₂O.

| Characteristics               | Non-VPS group (n = 23) | VPS group (n = 29) | P-value |
|-------------------------------|------------------------|-------------------|---------|
| Gender (M/F)                  | 23/0                   | 26/3              | 0.112   |
| Age, mean (SD)                | 38.9(12.5)             | 34.6(9.7)         | 0.178   |
| Days diagnosed AIDS before admission, mean (SD) | 283.6(729.8) | 98.0(399.0) | 0.258   |
| Headache, n (%)               | 20(87.0)               | 25(86.2)          | 0.849   |
| Fever, n (%)                  | 13(56.5)               | 18(62.1)          | 0.707   |
| Nausea, n (%)                 | 10(43.5)               | 22(75.9)          | 0.015   |
| Emesis, n (%)                 | 8(34.8)                | 20(69.0)          | 0.013   |
| Visual symptoms, n (%)        | 0(0.0)                 | 9(31.0)           | 0.002   |
| Hearing symptoms, n (%)       | 0(0.0)                 | 2(6.9)            | 0.183   |
| Cranial nerve palsy, n (%)    | 0(0.0)                 | 1(3.4)            | 0.351   |
| Mental status change, n (%)   | 4(17.4)                | 3(10.3)           | 0.460   |
| Neck stiffness, n (%)         | 18(78.3)               | 20(69.0)          | 0.453   |
| Convulsion, n (%)             | 0(0.0)                 | 5(17.2)           | 0.036   |
| KPS at baseline, mean (SD)    | 39.6(18.5)             | 39.3(21.3)        | 0.965   |
| KPS at 3 months, mean (SD)    | 58.3(47.0)             | 88.7(26.9)        | 0.012   |
| Ink stain, n (%)              | 22(95.7)               | 28(96.6)          | 0.867   |
| CSF culture, n (%)            | 16(69.6)               | 26(89.7)          | 0.116   |
| Cryptococcus counts, (10⁶/L), mean (SD) | 2.9(1.5)   | 3.5(1.8)         | 0.272   |
| CSF WBC, 10³/L, (SD)          | 15.7(31.5)             | 12.4(32.9)        | 0.716   |
| Glucose, mmol/L               | 2.7(0.7)               | 3.1(1.1)          | 0.110   |
| Protein, g/L, mean (SD)       | 0.5(0.2)               | 0.5(0.4)          | 0.457   |
| Chloride, mmol/L              | 115.7(5.6)             | 118.1(5.2)        | 0.122   |
| CD4, (10³/L), (SD)            | 10.1(14.8)             | 15.6(19.9)        | 0.309   |
| CD4/CD8, mean (SD)            | 0.080(0.06)            | 0.05(0.05)        | 0.124   |
| Hospital stay, mean (SD)      | 54.3(37.0)             | 61.6(88.0)        | 0.690   |
| Outcome at 1 month (Mortality rate), n (%) | 8(34.8) | 1(3.4)          | 0.003   |
| Outcome at 3 months (Mortality rate), n (%) | 9(39.1) | 2(6.9)          | 0.004   |
| Outcome at 6 months (Mortality rate), n (%) | 11(47.8) | 2(6.9) | 0.005 |
| Good MRS score at 3 months, n (%) | 14(60.9) | 26(89.7) | 0.014 |
| Good long-term MRS score, n (%) | 10(43.5) | 22(75.9) | 0.017 |

MRS, modified Rankin scale; SD, standard deviation; CSF WBC, cerebrospinal fluid white blood cell; VPS, ventriculoperitoneal shunt.

Postoperative complications

There were two cases of shunt infection, no ventriculitis, two cases of proximal catheter obstruction or displacement, no tube rupture, seven cases of excessive drainage, one case of too little drainage, no distal tube obstruction, no peritonitis, and two cases of abdominal shunt displacement. Of the two patients with shunt infection, one patient underwent shunt adjustment operation 2 months after operation, and the other removed the shunt tube approximately 1 year after operation. These two patients had a good outcome. There were two patients with proximal catheter obstruction or displacement and two others with shunt abdominal end displacement, and all of them underwent shunt adjustment. One patient with proximal catheter obstruction had a poor outcome, and the rest had a good outcome. The pressure of the patients with excessive drainage returned to normal after pressure regulation, and the outcome was good. One patient with too little drainage was complicated with proximal catheter obstruction and the outcome was poor.

Multivariate analysis

In logistic regression analysis, visual impairment (OR, 0.026; 95% CI, 0.001, 0.567; P = 0.021) and ICP > 350 mmH₂O (OR, 0.026; 95% CI, 0.002, 0.293; P = 0.003) were factors related to the placement of VPS (Table 3). In Cox regression analysis, KPS score (HR, 0.968; 95% CI, 0.943, 0.993; P = 0.013) and ICP > 350 mmH₂O (HR, 2.801; 95% CI, 1.035, 7.580; P = 0.043) were indices related to the outcome of patients with AIDS complicated with CM (Table 4).

Discussion

Even with the widespread use of highly active antiretroviral therapy (HAART), CM can kill approximately 15% of AIDS patients every year (14, 15). For AIDS patients with acute CM, it is important to realize that the deterioration of clinical conditions is caused by an increase of ICP. Graybill et al. (16) and Pappas et al. (17) indicate that the initial ICP of 50% AIDS patients complicated with CM is >250 mmH₂O. Dehydration drugs such as mannitol and acetazolamide have the effect of reducing intracranial pressure, but the effect is not significant, especially for acetazolamide, which can lead to a decrease of blood bicarbonate and an increase of blood chlorine, as well as some other adverse events. Many guidelines recommend continuous lumbar puncture for treatment, but it is difficult to quickly bring down ICP to normal level (18). VPS is a good method to control ICP in patients with CM. However, the indication
of VPS in AIDS patients complicated with CM and the indices associated with the outcome of VPS are unclear. It is generally believed that VPS should be performed in patients with hydrocephalus, but most patients are often not associated with an enlarged ventricular system (19, 20). A total of 96 patients in our study were not associated with ventricular enlargement, and while some patients underwent VPS, the outcome significantly improved. Therefore, we should seek the help of a neurosurgeon even without ventriculomegaly.

Identifying patients when they have AIDS complicated with CM diagnosis and who may require VPS may aid in improving the outcome. Baddley et al. (11) showed that ICP > 300 mmH2O and hydrocephalus were associated with VPS in CM patients. Our multivariable analysis showed that visual impairment and ICP > 350 mmH2O were associated with VPS in AIDS patients with CM.

TABLE 3 Logistic regression analysis of baseline factors associated with shunting.

| Variables               | Univariate OR (95% CI) | P-value | Multivariate OR (95% CI) | P-value |
|-------------------------|------------------------|---------|--------------------------|---------|
| Days diagnosed AIDS     | 0.999 (0.998,1.000)    | 0.196   | 0.999 (0.997,1.001)      | 0.289   |
| Visual symptoms         | 0.066 (0.013,0.332)    | 0.001   | 0.026 (0.001,0.576)      | 0.021   |
| KPS                     | 0.977 (0.955,0.999)    | 0.038   | 0.993 (0.962,1.025)      | 0.654   |
| Cryptococcus counts     | 1.409 (1.034,1.919)    | 0.030   | 1.322 (0.859,2.036)      | 0.204   |
| ICP > 350 mmH2O         | 0.018 (0.002,0.144)    | <0.001  | 0.026 (0.002,0.293)      | 0.003   |
| Neck stiffness          | 0.380 (0.152,0.951)    | 0.039   | 0.993 (0.212,4.653)      | 0.993   |

TABLE 4 Cox analysis of baseline factors associated with prognosis.

| Variables               | Univariate HR (95% CI) | P-value | Multivariate HR (95% CI) | P-value |
|-------------------------|------------------------|---------|--------------------------|---------|
| Headache                | 0.975 (0.335,2.836)    | 0.963   | 0.727 (0.239,2.213)      | 0.575   |
| Visual symptoms         | 1.074 (0.279,4.134)    | 0.917   | 1.122 (0.252,5.000)      | 0.880   |
| Neck stiffness          | 4.312 (1.034,1.919)    | 0.002   | 2.096 (0.771,5.695)      | 0.147   |
| KPS                     | 0.956 (0.932,0.981)    | 0.001   | 0.968 (0.943,0.993)      | 0.013   |
| ICP > 350 mmH2O         | 4.432 (1.836,10.699)   | 0.001   | 2.801 (1.035,7.580)      | 0.043   |

OR, odds ratio; CI, confidence interval; ICP, increased intracranial pressure.
Liang Wu et al. (13) analyzed 128 patients with AIDS complicated with CM, among which 24 underwent shunt surgery (5 with VPS and 19 with lumboperitoneal shunt). The author concluded that the outcome of patients undergoing shunt surgery was better than that of patients without shunt surgery.

Chih-Wei Hung et al. (5) analyzed 180 HIV-negative patients with CM and concluded that convulsions were associated with poor outcome and prolonged hospital stay. Anekthananon et al. (21) analyzed 140 cases of HIV-infected patients complicated with CM and concluded that factors associated with poor outcome at 14 days included high cryptococcal antigen titer (≥1:1024), low body weight, and low CSF white blood cell and factors associated with poor 70-day outcome included high cryptococcal antigen titer (≥1:1024) and low KPS score. However, prognostic indicators of VPS in these patients are lacking. Our study found that a low KPS score and ICP > 350 mmH2O were associated with poor outcome in patients with AIDS complicated with CM. Patients with low KPS scores may have progressive AIDS, which may lead to worse clinical outcomes. Uncontrollable increased ICP is defined as an extremely high pressure (>350 mmH2O) and failure to control symptoms with frequent lumbar punctures and the use of other medication such as mannitol, acetazolamide, or corticosteroids (5). In our study, the presence of ICP > 350 mmH2O indicates a poor outcome.

Although some patients with ICP > 350 mmH2O had a good outcome without VPS, in most patients with ICP > 350 mmH2O, VPS could significantly improve the outcome. Kaplan–Meier analysis showed that the 3-year survival rate of patients with VPS was significantly better than that of patients without VPS.

Common complications of VPS include obstruction, catheter rupture, dysfunction, infection (fungal infection or secondary infection), and excessive drainage. Other rare complications include subdural and intracranial hematoma, intestinal perforation, abdominal pseudocyst, hernia, and epilepsy (22). Subdural and intracerebral hematomas often occur in the cerebral ventricle, and atrophy of the brain and decompression of the ventricular system occur too quickly (23). If there is a high level of protein in the CSF, the risk of obstruction increases (24). A reasonable placement of the shunt tube can reduce the possibility of shunt blockage. If obstruction occurs, the shunt requires to be adjusted or even replaced. The concept of asepsis should be strictly borne in mind by the surgeon during the whole operation, and prophylactic use of antibiotics after shunt placement can reduce secondary infection. If infection occurs, it is necessary to remove the shunt tube and carry out anti-infective treatment. After the condition becomes stable, the tube should be placed again.

This study has several limitations. Although this is a large series of AIDS patients with CM managed with VPS, we were limited in our multivariable analyses due to only 30 shunt events. It is likely that we were unable to include some potentially important variables into the final multivariable model. This is a retrospective study, and therefore, it is subject to bias of some unmeasured factors. Also, during this study, the indication or frequency of lumbar punctures was not standardized, and thus we could not get more details about the alteration of ICP and the constituents of the CSF. Some scores, such as the Glasgow scale, were not evaluated in each patient, so this part of the data is missing. Our data may not be applicable in resource-limited settings where shunting is not available.

Conclusion

In summary, VPS was associated with better 3-year survival rates and good outcome, and postshunt placement complications like infections were rare as well. An identification of prognostic factors in the diagnosis of AIDS with CM and factors associated with VPS can improve the outcome of such patients. We opine that an analysis of the initial clinical data at the time of diagnosis of CM is very appropriate because it can reduce the impact caused by indications. For example, the timing and choice of shunt are related to the preferences of neurosurgeons and infectious disease surgeons. Given the small sample size of our study, more studies on VPS in patients with AIDS and CM are needed.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

Ethical approval for the study was obtained from the First Affiliated Hospital of Zhejiang University School of Medicine.

Author contributions

CZ, SY, and ZJS conceived the study. CZ, SY, and MR collected the data. CZ, MR, GJ, and ZPD analyzed the data. CZ, SY, and ZJS interpreted the data. CZ wrote the manuscript. SY and ZJS revised the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.942506/full#supplementary-material.

References

1. Brizendine KD, Pappas PG. Cryptococcal meningitis: current approaches to management in patients with and without AIDS. Curr Infect Dis Rep. (2010) 12:299–305. doi: 10.1007/s11908-010-0113-4

2. Longley N, Munozza C, Taseera K, Mweiguye J, Rwebewera J, Chakera A, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. (2008) 47:1556–61. doi: 10.1086/593194

3. Oladele RO, Bongomin F, Gago S, Denning DW. HIV-associated cryptococcal disease in resource-limited settings: a case for “prevention is better than cure”? J Fungi. (2017) 3(4):67. doi: 10.3390/jf3040067

4. Newton PN, Thai IH, Tipt QN, Short JM, Chierakul W, Rajanuwong A, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis. (2002) 35:769–72. doi: 10.1086/342299

5. Hung CW, Lin WC, Chang WN, Su TM, Kung CT, Tsai NW, et al. Risk factors and outcomes of cerebrospinal fluid overdrainage in HIV-negative patients with cryptococcal meningitis after the ventriculoperitoneal shunting procedure. J Microbiol Immunol Infect. (2018) 51:545–51. doi: 10.1016/j.jmii.2017.06.002

6. Johnston SR, Corbett EL, Foster O, Ash S, Cohen J. Raised intracerebral pressure and visual complications in AIDS patients with cryptococcal meningitis. J Infect. (1992) 24:185–9. doi: 10.1016/0163-4453(92)92954-h

7. Chan KH, Mann KS, Yue CP. Neurosurgical aspects of cerebral cryptococcosis. Neurosurgery. (1989) 25:44–8. doi: 10.1093/neuros/25.1.44

8. Wei B, Qian C, Liu Y, Lin X, Wan J, Wang Y. Ommaya reservoir in the treatment of cryptococcal meningitis. Acta Neurol Belg. (2017) 117:283–7. doi: 10.1007/s13760-016-0682-6

9. Loan JJM, Mankahla N, Meintjes G, Fieggen AG. Ventriculoperitoneal shunt insertion for hydrocephalus in human immunodeficiency virus-infected adults: a systematic review and meta-analysis protocol. Syst Rev. (2017) 6:201. doi: 10.1186/s13643-017-0603-7

10. Woodworth GF, McGirt MJ, Williams MA, Rigamonti D. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegaly secondary to HIV-associated cryptococcal meningitis. Surg Neurol. (2005) 63:329–31; discussion 331–332. doi: 10.1016/j.surneu.2004.08.069

11. Baddley JW, Thompson GR, Riley KO, Moore MK, Moser SA, Pappas PG. Factors associated with ventriculoperitoneal shunt placement in patients with cryptococcal meningitis. Open Forum Infect Dis. (2019) 6:ofz241. doi: 10.1093/ofid/ofz241

12. Bach MC, Tally PW, Godofsky EW. Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension. Neurosurgery. (1997) 41:1280–2; discussion 1282–1283. doi: 10.1093/neuros/41.6.1280

13. Wu L, Xiao J, Song Y, Gao G, Zhao H. The clinical characteristics and outcome of cryptococcal meningitis with AIDS in a tertiary hospital in China: an observational cohort study. BMC Infect Dis. (2020) 20:912. doi: 10.1186/s12879-020-05661-9

14. Cherian J, Atmar RL, Gopinath SP. Shunting in cryptococcal meningitis. J Neurosurg. (2016) 125:177–86. doi: 10.3171/2015.4.jns15255

15. Nyazika TK, Tatume JK, Kenfak-Foguena A, Verweij PE, Mbesi JF, Robertson VJ, et al. Epidemiology and aetiologies of cryptococcal meningitis in Africa, 1950–2017: protocol for a systematic review. BMJ Open. (2018) #e020664. doi: 10.1136/bmjopen-2017-020664

16. Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. (2000) 30:47–54. doi: 10.1086/313603

17. Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis. (2005) 40:480–2. doi: 10.1086/427222

18. Rajasingham R, Rolles MA, Birkenkamp KE, Meya DB, Boulware DR. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med. (2012) 9:e1001316. doi: 10.1371/journal.pmed.1001316

19. Lee SC, Casadevall A. Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis. Clin Infect Dis. (1996) 23:194–5. doi: 10.1093/clinicae/23.1.194

20. Petrou P, Moscovic S, Leker RR, Ishayik E, Gomori JM, Cohen JE. Ventriculoperitoneal shunt for intracranial hypertension in cryptococcal meningitis without hydrocephalus. J Clin Neurosci. (2012) 19:1175–6. doi: 10.1016/j.jocn.2012.01.008

21. Anekthananon T, Manousuthi W, Chetchotisakd P, Kiernthburanakul S, Supparatpinyo K, Ratanausawon W, et al. Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. Int J STD AIDS. (2011) 22:665–70. doi: 10.1258/ijlsa.2011.011058

22. Hauk L. Ventriculoperitoneal shunt. AORN J. (2018) 107:10–12. doi: 10.1002/aorn.12029

23. Maartens NF, Aurora P, Richards PG. An unusual complication of tapping a ventriculoperitoneal shunt. Eur J Paediatr Neurol. (2000) 4:125–9. doi: 10.1016/s0963-8543(00)00080-x

24. Kamat AS, Gretschel A, Vlok AJ, Solomon R. CSF protein concentration be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.942506/full#supplementary-material.